Inhibition of MRGPRX2 but not FcεRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist

Maram Bawazir1,2†, Aetas Amponnawarat1,3†, Yvonne Hui4, Carole A. Oskeritzian3 and Hydar Ali1*  

1Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, United States, 2Department of Oral Diagnostic Sciences, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia, 3Department of Family and Community Dentistry, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand, 4Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States

Mas-related G protein-coupled receptor-X2 (MRGPRX2) expressed on mast cells (MCs) contributes to hypersensitivity reactions to cationic US-Food and Drug Administration (FDA) approved drugs such as the neuromuscular blocking agent, rocuronium. In addition, activation of MRGPRX2 by the neuropeptide substance P (SP) and the pro-adrenomedullin peptide (PAMP-12) is associated with a variety of cutaneous conditions such as neurogenic inflammation, pain, atopic dermatitis, urticaria, and itch. Thus, small molecules aimed at blocking MRGPRX2 constitute potential options for modulating IgE-independent MC-mediated disorders. Two inverse MRGPRX2 agonists, named C9 and C9-6, have recently been identified, which inhibit basal G protein activation and agonist-induced calcium mobilization in transfected HEK293 cells. Substance P serves as a balanced agonist for MRGPRX2 whereby it activates both G protein-mediated degranulation and β-arrestin-mediated receptor internalization. The purpose of this study was to determine if C9 blocks MRGPRX2’s G protein and β-arrestin-mediated receptor internalization. The purpose of this study was to determine if C9 blocks MRGPRX2’s G protein and β-arrestin-mediated receptor internalization. We found that C9, and not its inactive analog C7, inhibited degranulation in RBL-2H3 cells stably expressing MRGPRX2 in response to SP, PAMP-12 and rocuronium with an IC50 value of ~300 nM. C9 also inhibited degranulation as measured by cell surface expression of CD63, CD107a and β-hexosaminidase release in LAD2 cells and human skin-derived MCs in response to SP but not the anaphylatoxin, C3a or FcεRI-aggregation. Furthermore, C9 inhibited β-arrestin recruitment and MRGPRX2 internalization in response to SP and PAMP-12. We found that a G protein-coupling defective missense MRGPRX2 variant (V282M) displays constitutive activity for β-arrestin recruitment, and that this response was significantly inhibited by C9.
Rocuronium, SP and PAMP-12 caused degranulation in mouse peritoneal MCs and these responses were abolished in the absence of MrgprB2 or cells treated with pertussis toxin but C9 had no effect. These findings suggest that C9 could provide an important framework for developing novel therapeutic approaches for the treatment of IgE-independent MC-mediated drug hypersensitivity and cutaneous disorders.

**KEYWORDS**
mast cell (MC), MRGPRX2, PAMP-12, substance P, rocuronium, antagonist, MRGPRX2 antagonist

**Introduction**

Mast cells (MCs) are tissue-resident immune cells that arise from hematopoietic lineage and are found close to peripheral nerve endings and blood vessels beneath the surface epithelium (1, 2). Although MCs are critical for host defense against microbial infection, they are best known for their roles in allergic disorders such as food allergy and asthma (1). These reactions are initiated following the cross-linking of high-affinity IgE receptors (FceRI) by allergens resulting in the release of histamine from secretory granules followed by newly synthesized mediators (3). Hypersensitivity reactions to Food and Drug Administration (FDA)-approved drugs such as neuromuscular blocking agents (NMBAs), fluoroquinolones, vancomycin, and radiographic contrast agents occur as a result of MC activation (1, 4). Since most patients with hypersensitivity reactions to drugs have not been previously exposed to the drug (5), an IgE-independent activation of MCs likely contributes to these reactions but the receptors involved remained a mystery until recently. In addition to FceRI, a subtype of MCs found predominantly in connective tissues express Mas-related G protein-coupled receptor X2 (MRGPRX2; mouse counterpart MrgprB2). The seminal observation by McNeil et al. (6), that all cationic drugs including NMBAs that induce hypersensitivity reactions

**Abbreviations:** BAT, basophil activation test; FceRI, high-affinity immunoglobulin E receptor; FITC, fluorescein isothiocyanate; IgE-CL, IgE receptor cross-linking; GPCR, G Protein-coupled receptor; MCs, mast cells; MFI, mean fluorescent intensity; MrgprB2, Mas-related G protein-coupled receptor B2; MRGPRX2, Mas-related G protein-coupled receptor X2; NMBAs, neuromuscular blocking agents; PAMP-12, pro-adrenomedullin peptide-12; PE, phycoerythrin; PTx, Pertussis toxin; PMCs, peritoneal mast cells; RBL-2H3, rat basophilic leukemia-2H3 cells; RBL-MRGPRX2, RBL-2H3 stably expressing MRGPRX2; rhSCF, recombinant human stem cell factor; MAT, mast cell activation test; MW, molecular weight; SCF, stem cell factor; SP, substance P; TANGO assay, transcriptional activation following arrestin translocation assay; WT, wild-type.

activate human and mouse MCs via MRGPRX2 and MrgprB2, respectively solved the mystery as to how these drugs could induce IgE-independent adverse reactions.

A unique feature of MRGPRX2 is that in addition to FDA-approved cationic drugs, it can be triggered by a wide range of endogenous agonists such as the neuropeptides substance P (SP), cortistatin, neuregulin, pro-adrenomedullin peptide (PAMP-12), eosinophil-derived major basic proteins and the host defense peptides (1, 7–10). Furthermore, MRGPRX2 has recently been implicated in the pathogenesis of mastocytosis (11), neurogenic inflammation (12), chronic urticaria (13), chronic prurigo (8), rosacea (14, 15), atopic dermatitis (16), and allergic contact dermatitis/itch (17). Thus, given the new and emerging role of MRGPRX2 on the pathogenesis of a variety of cutaneous conditions, the development of high-affinity receptor inhibitors may provide a novel approach for the modulation of these IgE-independent MC-mediated disorders (18).

Current strategies to modulate MRGPRX2 function involve direct inhibition of the receptor and its downstream signaling (10, 18, 19). It is noteworthy that although human MRGPRX2 and mouse MrgprB2 are activated by the same group of cationic ligands, there are important differences in the concentrations required to activate these receptors. Thus, EC50 value of SP towards MRGPRX2 is ~360-fold lower than that for MrgprB2. By contrast, the EC50 value of rocuronium for MRGPRX2 is ~12-fold higher than that for MrgprB2 (6, 20). This difference is attributed to the low amino acid sequence identity (~53%) between MRGPRX2 and MrgprB2 (21). Surprisingly, however, many of the small molecule inhibitors that attenuate MRGPRX2-mediated responses in human MCs in vitro also block MrgprB2-mediated responses in vivo. For example, it is generally accepted that the cathelicidin LL-37, which is elevated in the skin of rosacea patients, contributes to the disease through the activation of MCs via MRGPRX2 (14, 22). Callahan et al. (15), recently showed that osthole, a natural plant coumarin, inhibits LL-37-induced degranulation of human skin MCs in vitro and prevents LL-37-induced rosacea in mice. The authors
spontaneously proposed that osthole allosterically modulates MRGPRX2, and perhaps MrgrB2, to prevent LL-37-induced rosacea in mice. However, Roy et al. (14), showed that while MCs are required for LL-37-induced rosacea in mice, MrgrB2 does not fully mediate this response. In addition to MrgrB2, mouse connective tissue MCs express transcripts for MrgrB1, MrgrB8, and MrgrB13 (23, 24). It is therefore possible that in addition to MrgrB2, one or more of these receptors contribute to rosacea-like inflammation in mice and that osthole prevents this response by modulating multiple receptors in mouse MCs. Thus, to develop specific small molecule inhibitors to modulate MRGPRX2-mediated disorders, it is first critical to identify compounds that selectively inhibit MRGPRX2 but not MrgrB2 or other receptor-mediated signaling and mediator release in vitro.

In 2019, Ogasawara et al. (19), of Japan Tobacco Inc. screened an in-house library consisting of ~12,000 commercially available compounds for their ability to inhibit SP-induced Ca2+ mobilization in HEK293 cells stably expressing MRGPRX2. The authors identified two compounds designated as compound 1 (MW 223.6) and compound 2 (MW 223.6) that inhibit MRGPRX2-mediated calcium (Ca2+) mobilization and MC degranulation with an IC50 value of ~2 µM. However, for therapeutic utility, it is desirable to develop compounds that specifically block MRGPRX2 at concentrations lower than those reported for compounds 1 and 2. Recently, Cao et al. (25), utilized compounds 1 and 2 as templates to search the ZINC database (http://zinc15.docking.org) and performed two rounds of analog modeling in the ultra-large make-on-demand library. This led to the identification of two compounds, named C9 (MW 275) and C9-6 (MW 258) that serve as inverse agonists to inhibit MRGPRX2-mediated calcium (Ca2+) mobilization in transfected HEK293 cells without blocking responses to a number of other GPCRs (25). However, the possibility that these compounds inhibit MC degranulation in response to SP, PAMP-12, and rocuronium has not been determined. Also, their effects on MrgrB2 and IgE-mediated responses have not been determined.

In addition to G proteins, many MRGPRX2 agonists also cause β-arrestin recruitment to promote receptor internalization (26, 27). Furthermore, many naturally occurring missense MRGPRX2 variants have been identified that may contribute to the receptor’s role in either protecting from or promoting MC-mediated disorders (1, 28, 29). In the present study, we first sought to determine the effects of C9 on MRGPRX2-mediated G protein activation and Ca2+ mobilization in transfected HEK293 cells without blocking responses to a number of other GPCRs (25). However, the possibility that these compounds inhibit MC degranulation in response to SP, PAMP-12, and rocuronium has not been determined. Also, their effects on MrgrB2 and IgE-mediated responses have not been determined.

In addition to compounds 1 and 2, we also screened a library of ~12,000 commercially available compounds for their ability to inhibit MRGPRX2-mediated G protein activation and Ca2+ mobilization, degranulation, β-arrestin recruitment, and receptor internalization. We then asked whether it could modulate the constitutive activity of a missense variant of MRGPRX2. Finally, we sought to evaluate the specificity of C9 for MRGPRX2 by testing its ability to inhibit MrgrB2 and FcεRI-mediated degranulation in MCs. The data presented herein suggest that C9 could provide an important framework for developing novel and specific high-affinity small molecules to modulate MRGPRX2-mediated drug hypersensitivity and inflammatory disorders.

Materials and methods

Reagents

Cell culture reagents were purchased from Invitrogen (Carlsbad, CA); PAMP-12 from MedChem Express (Monmouth, NJ); Substance P from AnaSpec (Fremont, CA); Rocuronium from the Cayman chemical (Hayward, CA). Recombinant mouse interleukin-3 (IL-3), mouse stem cell factor (SCF), and recombinant human SCF (rhSCF) were obtained from Peprotech (Rocky Hill, NJ). Compounds C9 (2-sulfanyl-3-[(1,3-thiazol-2-yl)methyl]-3,4-dihydroquinazolin-4-one, MW 275), C9-6 (3-[(furan-2-yl)methyl]-2-sulfanyl-3,4-dihydroquinazolin-4-one, MW, 258), and C7 (3-[(2-pyridin-2-yl)ethyl]-2-sulfanyl-3,4-dihydroquinazolin-4-one, MW, 283), were obtained from Enamine LLC (Monmouth, NJ). PN200-219, N-acetyl-D-glucosamine (PNG) and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (St. Louis, MO). Fura-2 acetoxyethyl ester from Abcam (Cambridge, MA). Bright-Glo Luciferase was from Promega (Madison, WI). Lipofectamine™ 2000 transfection reagent from Invitrogen (Carlsbad, CA). PE anti-human MRGPRX2 antibody (Clone K125H4, Catalog 359004), FITC anti-human FcεRI (Clone AER-37, Catalog 334608), purified anti-human FcεRI (Clone AER-37, Catalog 334602), APC anti-human CD63 (Clone H5C6, Catalog 353008), and FITC anti-human CD107a (Clone H4A3, Catalog 328606) antibodies were from BioLegend (San Diego, CA). PE IgG2b Isotype control (Clone eB149/10H5, Catalog 12–4031–81) and FITC IgG isotype control (Clone eBio299Arm, Catalog 11–4888–81) antibodies were from Invitrogen (Carlsbad, CA). Pertussis toxin (PTx) was obtained from List Biological Laboratories (Campbell, CA).

Mice

Mice were housed in pathogen-free conditions and autoclaved hardwood bedding. Mice aged from 8 to 10 weeks old, and both genders were used in all experiments. C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and mice MrgrB2−/− mice were generated using CRISPR/Cas9 technology by CRISPR core of the University of Pennsylvania as previously described (30). Approval for the use of mice was obtained from the Institutional Animal Care and Use Committee at the University of Pennsylvania.
Cell line culture

RBL-2H3 cells stably expressing human MRGPRX2 (RBL-MRGPRX2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 mg/ml), and 1 mg/ml G418 (31). HTLA cells and cells stably expressing MRGPRX2-Tango (HTLA-MRGPRX2) were cultured similarly to RBL-2H3 cells in addition to the presence of hygromycin B (200 μg/ml), puromycin (5 mg/ml), and G418 (500 μg/ml) (32, 33). Laboratory of Allergic Diseases 2 (LAD2) cells were provided by Dr. A. Kirshenbaum and Dr. D. Metcalfe (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA). Cells were maintained in a complete StemPro-34 medium supplemented with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 μg/ml), and 100 ng/ml recombinant human stem cell factor (rhSCF). Weekly hemidepletions using media containing rhSCF were carried out as described (34).

Mouse peritoneal mast cell isolation and culture

Cells were isolated from peritoneal lavages of WT and MgrprB2−/− mice and were cultured for 4–8 weeks in complete Roswell Park Memorial Institute 1640 Medium (RPMI 1640) containing 10% FCS, penicillin (100 IU/ml), streptomycin (100 mg/ml), recombinant mouse IL-3 (10 ng/ml) and SCF (30 ng/ml). Cells were used within 4–8 weeks (27, 35). All cell cultures were kept at a 37°C incubator with 5% CO₂. Suspension cells were used later in the experiments as peritoneal MCs (PMCs) and purity of the cultured cells was determined by flow cytometry using anti-mouse c-kit and FcεRI antibodies (20).

Human skin-derived mast cell isolation and culture

Surgical skin samples were obtained through the Cooperative Human Tissue Network of the National Cancer Institute, as approved by the University of South Carolina’s Internal Review Board. Human skin MCs were collected and cultured from three individual donors, as described previously (20, 36). Briefly, subcutaneous fat was removed by blunt dissection, and the remaining tissue was chopped into 1- to 2-mm pieces before being digested for 2 h at 37°C with type 2 collagenase (1.5 mg/ml), hyaluronidase (0.7 mg/ml), and type 1 DNase (0.3 mg/ml) in HBSS. The dispersed cells were collected and resuspended in HBSS containing 1% FCS and 10 mM HEPES and filtered through a No. 80 mesh sieve. Cells were then resuspended in HBSS and layered over 75% Percoll in an HBSS cushion and centrifuged at 800×g at 37°C for 20 min. The interface between the buffer and Percoll was used to collect the nucleated cells. Percoll gradient-enriched cells were resuspended in a serum-free X-VIVO 15 medium containing rhSCF (100 ng/ml) at a concentration of 1 × 10⁶ cells/ml. MCs were used after 6–10 weeks of culture, toluidine blue staining was utilized to confirm the purity of MCs was approximately 100%.

Degranulation measured by β-hexosaminidase release assay

RBL-MRGPRX2 cells (5×10⁴ cells/well), LAD2 cells (1×10⁴ cells/well), primary human skin-derived MCs (5×10³ cells/well), and PMCs (1×10⁴ cells/well) were seeded into a 96-well plate in a total volume of 50 μl HEPES buffer containing 0.1% bovine serum albumin (BSA). Cells were preincubated in the absence or presence of MRGPRX2 antagonist for 5 min followed by the addition of SP, PAMP-12, or rocuronium for 30 min at 37°C. To determine the total β-hexosaminidase, cells were lysed in 50 μl of 0.1% Triton X-100. Aliquots (20 μl) of supernatants were incubated with 20 μl of 1 mM p-nitrophenyl-N-acetyl-b-D-glucosamine (PNAG) at 37°C for 1 h (RBL-MRGPRX2 cells), and 1.5 h (LAD2, primary human skin-derived MCs, and PMCs). Finally, 250 μl of stop solution was added (0.1 M Na₂CO₃/0.1 M NaHCO₃) to stop the reaction. The absorbance was measured with a microplate reader at a wavelength of 405 nm using a Versamax microplate spectrophotometer (Molecular Devices, San Jose, CA). Percentage of β-hexosaminidase degranulation was calculated by dividing the β-hexosaminidase release in the sample by total β-hexosaminidase release (37).

Degranulation measured by the surface expression of CD107a and CD63

MC degranulation was also assessed by flow cytometric measurement of cell surface CD107a (Lysosomal-Associated Membrane Protein 1, LAMP-1) and CD63 (LAMP-3) following agonist stimulation (38–40). LAD2 cells and human skin-derived MCs (1×10⁵ cells) were pre-incubated with compounds C9, C7, or vehicle control for 5 min at 37°C then stimulated with SP (0.3 μM), anti-human FcεRIα (Clone AER-37; 0.3 μg/ml) (41) or C3a (3 nM) for 5 min at 37°C. The cells were then immediately fixed with fixation buffer (Biolegend, Catalog 420801) for 15 min at room temperature. After washing with FACS buffer (PBS containing 2% fetal calf serum [FCS] and 0.02% sodium azide), non-specific binding was blocked with 1% BSA in PBS for 30 min at 4°C. Cells were exposed to FITC-conjugated anti-CD107a and APC-conjugated anti-CD63 antibodies for 30 min at 4°C. Cell surface expression of CD107a and CD63 were analyzed by a BD LSR II flow
cytometer (San Jose, CA) and FlowJo software version 10.7.2 (Tree Star Inc., Ashland, OR).

Calcium mobilization assay

RBL-MRGPRX2 cells (2 \times 10^6 cells) were loaded with Fura-2 acetoxymethyl ester (1 \mu M) in HEPES buffer containing 0.1% BSA for 30 min in the dark at 37°C, followed by 15 min period for de-esterification in dark at room temperature. Cells were washed and resuspended in HEPES-buffered saline and Ca^{2+} mobilization was measured for the designated time. Calcium mobilization was determined by measuring the fluorescence ratio between dual excitation wavelengths of 340 and 380 nm, and an emission wavelength of 510 nm using a Hitachi F-2700 Fluorescence Spectrophotometer (29).

Generation of HTLA cells transiently expressing MRGPRX2 and V282M missense

Transient transfection of HTLA cells to express MRGPRX2 or its missense V282M variant was performed as described previously (29, 35). Briefly, HTLA cells (2 \times 10^6 cells) were plated in a 6-well plate in a complete medium and incubated overnight at 37°C. Cells were transiently transfected the next day with 2 \mu g of MRGPRX2 or its variant V282M in Tango plasmids using Lipofectamine™ 2000 DNA transfection reagent, according to the manufacturer protocol. Cells were then incubated in an antibiotic-free medium (DMEM supplemented with 10% FBS and L-glutamine) overnight at 37°C with 5% CO₂ and used within 16-24 h after transfection.

Transcriptional activation following arrestin translocation (TANGO) assay

HTLA cells stably expressing MRGPRX2 (5 \times 10^6 cells/well) were plated into a 96-well plate with an antibiotic-free medium and incubated for 6 h to allow cells’ adherence at 37°C with 5% CO₂. Following 6 h of incubation, the medium was aspirated, and cells were incubated with C9 (1 or 10 \mu M) in an antibiotic-free medium for 5 min, followed by stimulation with MRGPRX2 agonist for an additional 16 h at 37°C with 5% CO₂ incubator. After 16 h, the medium was aspirated and replaced with 100 \mu l of Bright-Glo solution (Promega). The relative luminescence unit was measured in a Thermo Labsystems Luminoskan Ascent 392 Microplate Luminometer (42). For HTLA cells transiently transfected with MRGPRX2 or its missense variant, V282M tango plasmid, cells treated with C9 (10 \mu M), C7 (10 \mu M), or non-treated control and assay were performed similarly (32).

MRGPRX2 internalization

RBL-MRGPRX2 or HTLA-MRGPRX2 cells (0.5x10^6 cells), and LAD2 cells (0.3x10^6 cells) were stimulated with SP, PAMP-12, and rocuronium in the presence and absence of C9. Cells were washed and suspended in FACS buffer (PBS containing 2% fetal calf serum [FCS] and 0.02% sodium azide) and incubated with the PE-conjugated anti-MRGPRX2 antibody for 30 min at 4°C in the dark. Cells were washed in FACS buffer, fixed in 1.5% paraformaldehyde and acquired using a BD LSR II flow cytometer (San Jose, CA) and analyzed with the FlowJo software version 10.8.1 (Tree Star Inc., Ashland, OR).

Statistical analysis

GraphPad PRISM software version 9.0.1 (San Diego, CSA) was used to perform the statistical analysis. Results were expressed as mean ± standard error of the mean (SEM) values. SEM values were derived from three independent experiments. Statistical significance was measured by t-test for single comparisons and one-way analysis of variance (ANOVA) or two-way ANOVA for multiple comparisons. A P-value ≤ 0.05 was considered to be significant.

Results

Compounds C9 and C9-6 inhibit substance P, PAMP-12, and rocuronium-induced degranulation and Ca^{2+} mobilization in RBL-2H3 cells stably expressing MRGPRX2

ZINC-3573 has been identified as a potent MRGPRX2 agonist (33). Using calcium mobilization as an assay in HEK293 cells stably expressing MRGPRX2, Cao et al. (25), showed that C9 and C9-6 inhibit ZINC-3573-induced responses with Ki values of 43 nM and 58 nM, respectively. C9 also inhibited ZINC3573-induced degranulation in a human MC line (LAD2 cells) endogenously expressing MRGPRX2 but with an IC_{50} value of >1 \mu M (25). However, an inactive analog of C9, known as C7, had no inhibitory activity on ZINC3573-induced responses in HEK293 cells or LAD2 cells. We first sought to determine the effects of C9, C9-6, and C7 on degranulation in response to two endogenously generated MRGPRX2 agonists (SP and PAMP-12) that contribute to a variety of MC-dependent disorders and an FDA-approved drug that is associated with hypersensitivity (rocuronium). For this, we preincubated RBL-2H3 cells stably expressing MRGPRX2 (RBL-MRGPRX2) with C9, C9-6, or C7 (10 \mu M, 5 min) and tested their effects on \beta-hexosaminidase release in response to SP (0.3 \mu M), PAMP-12 (0.3 \mu M) and rocuronium (1 mg/ml). As shown in
Figure 1A, C9 and C9-6 abolished degranulation in response to these agonists but C7 had no effect. For subsequent studies, we used C9 and the inactive analog C7, where appropriate.

To determine the minimal concentration of C9 required to cause significant inhibition of degranulation, we preincubated RBL-MRGPRX2 cells with different concentrations of C9 (0.01 µM – 10 µM, 5 min) and assessed β-hexosaminidase release in response to SP, PAMP-12, and rocuronium. C9 inhibited degranulation in response to all agonists tested in a dose-dependent manner with an IC₅₀ value of ~0.3 µM (Figures 1B–D). Because Ca²⁺ mobilization is required for MC degranulation, we tested the effect of C9 on SP and PAMP-12-induced Ca²⁺ response in RBL-MRGPRX2 cells. For this, Fura-2-loaded cells were preincubated with C9 (10 µM, 5 min) and exposed to SP or PAMP-12 (0.3 µM) and Ca²⁺ mobilization was measured continuously for the next 10 min. We found that C9 caused substantial inhibition of the Ca²⁺ response to both agonists at all time points tested (Figures 1E, F).

C9 inhibits MRGPRX2-mediated degranulation in LAD2 cells and human skin MCs without affecting C3a receptor and FceRI-mediated responses

LAD2 cell is a human MC line that endogenously expresses MRGPRX2 and C3a receptor (C3aR) and has been used extensively to GPCR function in MCs (35, 43, 44). We, therefore, sought to determine if C9 inhibits degranulation in response to MRGPRX2 agonists. As shown in Figure 2A, preincubation of LAD2 cells with C9, but not C7 (1 µM, 5 min), resulted in a substantial reduction of SP, PAMP-12, and rocuronium-induced degranulation as measured by β-hexosaminidase release. CD107a and CD63 are granule-associated proteins that undergo externalization during the degranulation (45). We found that both SP and the anaphylatoxin C3a, caused increased cell surface expression of CD107a and CD63, as measured by flow cytometry (Figures 2B, C). Furthermore, preincubation of LAD2 cells with C9 (1 µM, 5 min), but not C7, abolished the SP response. By contrast, C9 or C7 had no effect on C3a-induced cell surface expression of CD107a and CD63. Quantitative results are shown in Figures 2D, E.

To determine the biological relevance of the findings in LAD2 cells, we performed selected experiments with primary human skin-derived MCs obtained from three healthy donors. When the purity of cultured MCs reached ~100%, flow cytometry was used to determine MRGPRX2 and FcεRI expression (Figures 3A–C). Consistent with MRGPRX2 expression, skin MCs from donors 1 and 3 responded to SP for degranulation, as assessed by β-hexosaminidase release and this response was significantly inhibited by C9 (1 µM) (Figures 3D–F). Although MCs from all three donors expressed cell surface FcεRI, those from donors 1 and 2 responded to FcεRlI-aggregation for β-hexosaminidase

![Figure 1](image-url)
release but this response was resistant to inhibition by C9 (Figures 3D–F). To further validate the specificity of C9, we tested its ability to inhibit cell surface CD107a and CD63 expression in response to SP and FcεRIα-aggregation. In agreement with the β-hexosaminidase release, SP (donor 1 and donor 3) and FcεRIα-aggregation (donor 1 and donor 2) induced significant upregulation of cell surface CD107a and CD63 (Figures 4A–C). C9 significantly blocked SP, but not FcεRIα-aggregation responses (Figures 4A–C). The quantification of flow cytometry data is shown in Figures 4D–F. Together, these findings demonstrate that C9 specifically inhibits MRGPRX2-mediated MC degranulation without affecting the responses to C3a or FcεRIα-aggregation.

Pre-incubation of RBL-MRGPRX2 cells with C9 is not required for its ability to inhibit MRGPRX2-mediated Ca2+ mobilization and degranulation

For experiments described above, cells were preincubated with C9 for 5 min before exposure to stimulants. We next sought to determine if C9 could reverse an ongoing MRGPRX2-mediated response using Ca2+ mobilization as an assay in RBL-MRGPRX2 cells. As shown in Figure 5A, when C9 was added 100 sec after stimulation with SP, it caused an immediate and significant reduction of the response for the entire duration of the experiment when compared to C7 control. Our next goal was to determine the effect of C9 on ongoing degranulation in response to SP. For this, we first assessed the time-course (1 to 30 min) of SP-induced β-hexosaminidase release. As shown in Figure 5B, SP caused half-maximal degranulation at 2.5 min after stimulation and the reaction reached a maximal value at 15 min after stimulation. Next, for one set of experiments, we stopped the reaction at 2.5 min after stimulation with SP. For the second set, we added C9 at 2.5 min after SP stimulation and allowed degranulation to proceed until 15 min. As shown in Figure 5C, there was no significant difference in SP-induced degranulation at 2.5 min without C9 when compared to the response at 15 min after the addition of C9 at 2.5 min. These findings clearly demonstrate that C9 is able to stop an ongoing Ca2+ mobilization and degranulation in response to SP.

C9 inhibits MRGPRX2-mediated β-arrestin recruitment and receptor internalization

Using transcriptional activation following arrestin translocation (TANGO) assay in HTLA cells stably expressing...
MRGPRX2 (HTLA-MRGPRX2), we previously showed that SP causes β-arrestin translocation and that this is associated with receptor internalization (27, 33). However, the possibility that PAMP-12 causes β-arrestin signaling has not been determined. Thus, we first tested the ability of all 3 agonists to cause β-arrestin translocation using the TANGO assay. Cells were exposed to either buffer (control) or agonists for 16 h and β-arrestin-mediated gene expression (indicative of β-arrestin recruitment) was measured. As per previous report, we found that SP induced substantial β-arrestin recruitment, and that PAMP-12 also induced a similar response (Figure 6A). Lansu et al. (33), reported that rocuronium at a concentration of 100 µM does not induce TANGO in HTLA-MRGPRX2 cells. However, we found that rocuronium at a concentration of 300 µM induces a significant β-arrestin signal, which was similar in magnitude to that induced by SP and PAMP-12 (Figure 6A). To determine if C9 inhibits β-arrestin recruitment, we preincubated HTLA-MRGPRX2 cells with different concentrations of the antagonist and quantitated using the TANGO assay. We found that C9 at a concentration of 1 µM caused significant inhibition of response to all three agonists (Figure 6A).

To determine the effect of C9 on receptor internalization, HTLA-MRGPRX2 cells, RBL-MRGPRX2 cells, and LAD2 cells were preincubated with C9, then exposed to SP, PAMP-12, and rocuronium, and receptor internalization was assessed by determining loss of cell surface receptor expression by flow cytometry. In all three cell types, SP and PAMP-12 caused MRGPRX2 internalization and C9 inhibited this response but the magnitude of inhibition was greater in RBL cells when compared to HTLA, or LAD2 cells (Figures 6B–D).

Interestingly, although rocuronium induced substantial β-arrestin recruitment, this was not associated with MRGPRX2 internalization in HTLA, RBL, or LAD2 cells (Figures 6A–D).

Constitutive β-arrestin recruitment in response to a naturally occurring missense MRGPRX2 variant is inhibited by C9

We recently identified a naturally occurring MRGPRX2 missense variant (V282M) that displays a loss of function phenotype for G protein-mediated degranulation (29, 35). We found that transient transfection of HTLA cells resulted in a similar level of cell surface expression of the V282M variant when compared to the wild-type receptor (Figure 7A). Interestingly, this response was significantly inhibited by C9 but not by its inactive analog, C7 (Figure 7B).

C9 does not inhibit MrgprB2-mediated degranulation in mouse peritoneal MCs

Although MRGPRX2 and MrgprB2 share the same agonists there are important differences in the concentrations of SP and rocuronium required to activate these receptors (6). Consistent with previous reports, we found that SP at 100 µM induced only a small and variable degranulation, as measured by β-
FIGURE 4
C9 inhibits the upregulation of cell surface expression of CD107a and CD63 in response to SP in human skin-derived MCs. (A–C) Cells from three donors were preincubated with buffer or C9 (1 µM, 5 min), stimulated with SP (0.3 µM) or FcεRIα-aggregation antibody, IgE-CL (0.3 µg/ml) for an additional 5 min and cell surface expression of CD107a and CD63 was determined by flow cytometry. Representative histograms of CD107a and CD63 expression are shown. (D–F) The mean fluorescent intensity (MFI) levels of CD107a and CD63 are shown. Data are expressed as mean ± SEM. Statistical significance was determined by two-way ANOVA test at a value **P < 0.01, ***P < 0.001, and ****P < 0.0001.

FIGURE 5
Pre-incubation of cells with C9 is not required for its ability to inhibit MRGPRX2-mediated Ca2+ mobilization and degranulation. (A) Ca2+ mobilization measurement of Fura-2 loaded RBL-MRGPRX2 cells following stimulation with SP (3 µM). As the response approached the plateau phase, the C9 or C7 (10 µM) was introduced and the response was measured for an additional 5 min. (B) RBL-MRGPRX2 cells were exposed to SP (0.3 µM) and the time-course of degranulation was assayed by measuring the release of β-hexosaminidase. (C) Cells were exposed to SP (0.3 µM) and degranulation was quantitated after 2.5 min (left, purple) or 15 min (right purple). Alternatively, cells were stimulated with SP for 2.5 min and then exposed to C9 (10 µM) for an extra 12.5 min (total of 15 min), and β-hexosaminidase release was determined (middle, pink). Data are expressed as mean ± SEM. Statistical significance was determined by unpaired t-test for single comparison and one-way ANOVA for multiple comparisons at a value *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ns denotes "not significant".
FIGURE 6
C9 inhibits MRGPRX2-mediated β-arrestin recruitment and receptor internalization. (A) HTLA-MRGPRX2 cells were preincubated with C9 (1 µM and 10 µM, 5 min) and then exposed to SP, PAMP-12, or rocuronium for 16 h. The medium was removed and substituted with the Bright-Glo solution (100 µl/well) in a 96-well plate. β-arrestin translocation-mediated gene expression was quantitated as a relative luminescence unit. (B-D) Quantitative analysis of receptor internalization in (B) HTLA-MRGPRX2, (C) RBL-MRGPRX2, and (D) LAD2 cells. Cells were preincubated with C9 (10 µM, 5 min), exposed to buffer or MRGPRX2 agonists (30 min) and cell surface receptor expression was determined by flow cytometry. The percentage of receptor internalization was calculated using a mean fluorescent intensity (MFI) in comparison to the untreated or vehicle controls. Data are expressed as mean ± SEM. Statistical significance was determined by two-way ANOVA test at a value *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

FIGURE 7
Constitutive β-arrestin recruitment in response to a naturally occurring missense MRGPRX2 variant is inhibited by C9. (A) HTLA cells transiently expressing MRGPRX2 (WT-X2) and its variant V282M were incubated with PE-conjugated anti-MRGPRX2 antibody or isotype controls and the cell surface receptor expression was determined by flow cytometry. (B) Cells were exposed to C9 (10 µM) or C7 (10 µM) without any agonist stimulation. After 16 h, the medium was removed and substituted with Bright-Glo solution (100 µl/well) in a 96-well plate. β-arrestin gene translocation-mediated gene expression was measured in a relative luminescence unit. Data are expressed as mean ± SEM. Statistical significance was determined by two-way ANOVA test at a value *P < 0.05 and ****P < 0.0001.
hexosaminidase release, but rocuronium at 20 µg/ml caused a substantial response in mouse PMCs (Figure 8A) (20). We first validated that degranulation in response to SP, PAMP-12, and rocuronium is mediated via MrgprB2 by demonstrating that PMCs cultured from MrgprB2−/− mice do not respond to these agonists (Figure 8A). Although inhibition of Gαi proteins by pertussis toxin (PTx) leads to almost complete inhibition of MRGPRX2-mediated degranulation in human CD34− cell-derived MCs (19), its effect on MrgprB2-mediated degranulation is unknown. We therefore preincubated PMCs from WT mice with pertussis toxin (PTx; 100 ng/ml for 16 h) and tested the ability of SP, PAMP-12, and rocuronium to induce degranulation. The result presented in Figure 8B shows that PTx-pretreatment almost completely blocked β-hexosaminidase release in response to all three agonists, suggesting that, similar to MRGPRX2, MrgprB2-mediated response is mediated by Gαi. Next, we tested the ability of C9 (10 µM) to inhibit MrgprB2-mediated degranulation in PMCs generated from WT mice. Because SP induces a small and variable response, we utilized PAMP-12 and rocuronium for this set of experiments. Interestingly, we found that C9 was unable to inhibit MrgprB2-mediated β-hexosaminidase release (Figure 8C). The results from these studies demonstrate that similar to MRGPRX2 in human MCs, PAMP-12 and rocuronium couple to MrgprB2 and Gαi proteins but C9 is highly specific to human receptor MRGPRX2.

Discussion

It is well documented that IgE-mediated MC activation participates in food allergy, anaphylaxis, and asthma. However, there has been an explosion in interest in the role of non-IgE-mediated MC activation, in particular MRGPRX2, on drug-induced hypersensitivity and a variety of cutaneous disorders. Cao et al. (25), recently identified C9, as a small molecule inverse agonist of MRGPRX2, which inhibits basal G protein activation and blocks ZINC-3573-induced calcium mobilization in transfected HEK293 cells. In the present study, we utilized transfected cell lines (RBL and HTLA), a human MC line endogenously expressing MRGPRX2 (LAD2), primary human skin-derived MCs, and mouse peritoneal MCs derived from WT and MrgprB2−/− mice to show that C9 specifically inhibits MRGPRX2-mediated degranulation without affecting responses to FcεRI or MrgprB2.

Cao et al. (25), showed that C9 inhibits ZINC-3573-induced Ca2+ mobilization in transfected HEK293 cells with a Ki value 43 nM. However, C9 at 1 µM inhibited ZINC-3573-induced degranulation in LAD2 cells by <50% and required >10 µM for almost complete inhibition of degranulation. The reason for this difference is not clear but could reflect the agonist and cell types used. Our studies focused on three MRGPRX2 agonists that are implicated in a variety of cutaneous conditions and drug-induced hypersensitivity. However, unlike the situation with ZINC-3573 (25), C9 inhibited degranulation in response to SP, PAMP-12 and rocuronium with an IC50 value of ~300 nM and 1 µM of the compound caused substantial inhibition of the response. Cryo-EM structure of MRGPRX2 with a number of agonists has recently been resolved (25, 46). MRGPRX2 has two binding pockets, one with the negative charge and the other with hydrophobic residues (25). The neuropeptide cortistatin utilizes both pockets for binding whereas the synthetic small molecule MRGPRX2 agonist ZINC-3573 binds only to one pocket. Whether this difference reflects the high concentration of C9 required to inhibit degranulation induced by ZINC-3573 in LAD2 cells remains to be determined (25).

Since the description of CD63 as a surface degranulation marker, a flow cytometry-based assay known as basophil activation test (BAT) was developed and has been reliably used for the diagnosis of IgE-mediated allergic responses (47). As LAD2 cells and human peripheral CD34− cell-derived MCs express MRGPRX2, a flow cytometric assay, known as MC activation test (MAT) that quantitates cell surface expression of CD63 and CD107a has been developed, which could be used to test MRGPRX2 activation by sera of patients undergoing drug hypersensitivity reactions (45, 48). Navines-Ferrer et al. (49), recently utilized CD63 upregulation as a measure of MC degranulation by sera obtained from healthy controls and patients who had experienced an anaphylactoid reaction due to drug administration. It was demonstrated that sera from patients who had undergone anaphylactoid reactions induced an upregulation of CD63 expression on LAD2 cells and that this response was reduced in MRGPRX2-silenced cells. Based on these findings, it was concluded that MRGPRX2 is a candidate for mediating hypersensitivity reactions. In the present study, we utilized MAT to show that while SP and C3a caused MC degranulation, C9 at 1 µM selectively blocked SP-induced response. In primary human skin-derived MCs, both SP and FcεRI-aggregation caused increased expression of CD63 and CD107a but C9 blocked the response to SP, but not FcεRI-aggregation. These findings suggest that C9 could be utilized as a novel diagnostic tool to determine the role of MRGPRX2 not only in drug-induced hypersensitivity but also in other MC-mediated disorders.

Sugammadex is a modified γ-cyclodextrin that reverses neuromuscular blockade by encapsulating rocuronium and atracurium and removing it from the neuromuscular junction. Coincubation of atracurium with sugammadex, in molar excess, inhibits atracurium and rocuronium-induced MRGPRX2-mediated MC activation (50, 51). However, given that sugammadex does not stop atracurium-induced MC degranulation, once initiated, it is unlikely to be useful in patients with ongoing atracurium or rocuronium-mediated perioperative anaphylaxis (51–53). We have shown that preincubation of RBL-MRGPRX2 cells with C9 is not required for its ability to block SP-induced Ca2+ mobilization and degranulation. Thus, when cells were exposed to SP for Ca2+...
mobilization, the response was reversed almost immediately after C9 was added. Similarly, ongoing degranulation was also halted immediately after the addition of C9. These findings have clinical implications for the potential utilization of C9 or its derivatives for targeting MRGPRX2-mediated drug hypersensitivity and inflammatory disorders. Thus, it will be interesting to see if prophylactic administration of C9 or a similar drug before surgical procedures lowers overall perioperative patient...
mortality. Given that SP and PAMP-12 are implicated in urticaria, atopic dermatitis, and allergic contact dermatitis, it should be possible to utilize C9 or small molecules based on this compound for topical application to treat these conditions.

In addition to G protein, SP also couples to β-arrestin-mediated signaling to promote receptor internalization (27). We found that PAMP-12 also induced β-arrestin recruitment and receptor internalization. Interestingly, C9 inhibited both SP and PAMP-induced β-arrestin recruitment in HTLA cells. C9 also blocked SP and PAMP-12-induced MRGPRX2 internalization but the magnitude of the inhibition was dependent on whether the experiment was performed in transfected RBL-2H3 cells, HTLA cells, or LAD2 cells which endogenously express MRGPRX2. Rocuronium caused robust β-arrestin recruitment, which was inhibited by C9. However, rocuronium induced minimal MRGPRX2 internalization in transfected RBL-2H3 and HTLA cells as well as LAD2 cells. This suggests that depending on the ligand used, β-arrestin recruitment could be dissociated from receptor internalization. Despite this difference, it is clear that C9 inhibits both G protein and β-arrestin-dependent signaling. From a mechanistic standpoint, Cao et al. (25), showed that C9 inhibits basal recruitment of Gβγ by MRGPRX2, thus exhibiting inverse agonist activity. Our finding that C9 also causes significant inhibition of constitutive β-arrestin recruitment by the missense MRGPRX2 variant V282M, supports the notion that it serves as an inverse agonist. However, the original compounds (compound 1 and 2) from which C9 was derived inhibit SP binding to MRGPRX2 and block GTP-γS binding activities of a Gα protein (19). Based on these findings, it was proposed that they serve as competitive antagonists of MRGPRX2. Additional studies will be required to determine the exact mechanism via which compound 1, 2 and C9 inhibit MRGPRX2-mediated responses in MCs.

In summary, we have shown that C9 is a potent and selective inhibitor of MRGPRX2-mediated MC degranulation using three different assays; cell surface expression of CD63, CD107a and β-hexosaminidase release. MRGPRX2 is highly polymorphic and most of the missense mutants remain uncharacterized (1). We have shown that the V282M missense mutation, which displays a loss of function phenotype for G protein activation and MC degranulation, promotes constitutive activity for β-arrestin recruitment and that C9 inhibits this response. It is possible that certain individuals display a gain of function phenotype for degranulation contributing to MRGPRX2-mediated disorders. It should be feasible to generate MCs from the peripheral blood of these individuals and determine if C9 inhibits constitutive activity. Elevated expression of MRGPRX2 has been reported in skin MCs of patients with allergic contact dermatitis, chronic spontaneous urticaria, rosacea, and mastocytosis (11, 13, 14, 54). Beyond the skin, MRGPRX2-expressing MCs are increased in the gingiva of patients with chronic periodontitis, and lung MCs of individuals who died from asthma (55, 56). Thus, there is tremendous therapeutic potential for utilizing small molecule MRGPRX2 blockers to modulate a variety of MC-mediated disorders. Compound C9 could be the starting point for developing such therapeutics but bioavailability, stability, toxicity, and its possible off-target effects need to be determined. Furthermore, given that C9 does not modulate MrgprB2-mediated MC degranulation, preclinical studies will require humanized mice or transgenic mice that express MRGPRX2 in MCs.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

HA contributed to the conception and supervision. HA and CO contributed to funding acquisition of the study. MB and AA performed the experiments and analyzed the data. YH and CO provided human skin MCs for the study. MB, AA, and HA wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants R01-AI143185, R01-AI149487, and R01-AI124182 to HA; and R21-AR067996 and P20 GM-103641 to CO.

Acknowledgments

We thank the FACS core facility of the University of Pennsylvania School of Dental Medicine for flow cytometry acquisition and analysis.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Roy S, Chompunud Na Ayudhya C, Thapaliya M, Deepak V, Ali H. Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease. J Allergy Clin Immunol (2021) 148(2):293–308. doi: 10.1016/j.jaci.2021.03.049.

2. Varriano G, Pecoraro A, LoPredo S, Poto R, Rivellese F, Genovese A, et al. Heterogeneity of human mast cells with respect to MRGPRX2 receptor expression and function. Front Cell Neurosci (2019) 13:299. doi: 10.3389/fncel.2019.00299.

3. Ali H. Regulation of human mast cell and basophil function by unanayphotins C3a and C5a. Immunol Lett (2010) 128(1):36–45. doi: 10.1016/j.imml.2009.10.007.

4. McNeil BD. MRGPRX2 and adverse drug reactions. Front Immunol (2021) 12:676354. doi: 10.3389/fimmu.2021.676354.

5. Fisher MM, Munro I. Life-threatening anaphylactoid reactions to muscle relaxants. Anesth Analg (2019) 128(1):22. doi: 10.1213/00000539-198306000-00003.

6. McNeil BD, Pandur P, Meeker S, Han I, Undem BJ, Kulkia M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature (2015) 519(7542):237–41. doi: 10.1038/nature14102.

7. Tatemoto K, Noraki Y, Tsuda R, Konno S, Tomura K, Furuno M, et al. Immunoglobulin G1-independent activation of mast cell is mediated by mrg2 receptors. Biochem Biophys Res Commun (2006) 349(4):1322–8. doi: 10.1016/j.bbrc.2006.08.177.

8. Kolkkar P, Pyszlova P, Ashby T, Jiao Q, Abad-Perez AT, Allrichter S, et al. Mast cells, cortisatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. J Allergy Clin Immunol (2022) 149(6):1998–2009. e5. doi: 10.1016/j.jaci.2022.02.021.

9. Matsu Y, Yanase Y, Irifuku R, Takahagi S, Mihara S, Ishii K, et al. Neuregulin 1 delta 1 directs degranulation of skin mast cells, presumably via MRGPRX2. Allergy (2018) 73(11):2256–60. doi: 10.1111/all.13555.

10. Ogasawara H, Furuno M, Edamura K, Noguchi M. Peptides of major basic protein and eosinophil cationic protein activate human mast cells. Biochim Biophys Acta (2020) 21:100719. doi: 10.1016/j.bbrp.2019.100719.

11. Deepak V, Komarow HD, Albluhes AA, Carter MC, Metcalfe DD, Ali H. Expression of MRGPRX2 in skin mast cells of patients with maculopapular disease. Allergol Int (2020) 134:3(6):322–39. doi: 10.1016/j.jaci.2021.05.004.

12. Green DP, Limjanta Wongwong N, Gour N, Pandur P, Dong X. A mast-cell-specific receptor mediates neurogenic inflammation and pain. Neuron (2019) 101(3):412–20. e3. doi: 10.1016/j.neuron.2019.01.012.

13. Fujisawa D, Kashiuwaraka J, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto T, et al. Expression of mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol (2014) 134(3):622–33.e9. doi: 10.1016/j.jaci.2014.05.004.

14. Roy S, Alkanfari I, Chaki S, Ali H. Role of MrgprX2 in rosacea-like inflammatory disease. Front Immunol (2021) 9(10):3841. doi: 10.3389/fimmu.2021.676354.

15. Alkanfari I, Freeman KB, Roy S, Jahan T, Scott RW, Ali H. Small-molecule host-defense peptide mimetic antibacterial and antifungal agents activate human and mouse mast cells via muscarinic GPCRs. Cells (2019) 8(4):311. doi: 10.3390/cells08040311.

16. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, et al. PRESTO-tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol (2021) 25(3):362–9. doi: 10.1038/s41590-019-03014.

17. Plum T, Wang X, Rettel M, Krijgsveld J, Feyerabend TB, Rodewald HR. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and MHC. Blood (2003) 101(15):4354–60. doi: 10.1182/blood.V101.15.4354-4359.

18. Kim HS, Hashimoto T, Fischer K, Bernigaud C, Chisovod O, Yospinovitch G. Scabies itch: an update on neurotransmitter interactions and novel targets. J Eur Acad Dermatol Venereol (2021) 35(9):1765–76. doi: 10.1111/jdv.17334.

19. Ogasawara H, Noguchi M, The Murepavadin, a nanomolar selective αvβ6 integrin antagonist, does not induce inflammation of skin mast cells. J Allergy Clin Immunol (2020) 125(1):54–52. doi: 10.1111/jaci.15734.

20. Chompunud Na Ayudhya C, Amponnawarat A, Roy S, Uskertizan CA, Ali H. MRGPRX2 activation by rocuronium: Insights from studies with human skin mast cells and mice. J Cell Physiol (2021) 21(10):156. doi: 10.1002/jcp.29156.

21. Subramanian H, Gupta K, Ali H. Roles of mas-related G protein-coupled receptor X2 on mast cell-mediated defense, pseudopodular drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol (2016) 138(3):700–10. doi: 10.1016/j.jaci.2016.04.051.
41. Babina M, Wang Z, Li Z, Franke K, Guel S, Artuc M, et al. FcepsilonRI- and MRGPRX2-evoked acute degranulation responses are fully additive in human skin mast cells. *Allergy* (2022) 77(6):1906–9. doi: 10.1111/all.15270

42. Roy S, Ganguly A, Haque M, Ali H. Angiogenic host defense peptide AG-30/5C and bradykinin B(2) receptor antagonist icatibant are G protein biased agonists for MRGPRX2 in mast cells. *J Immunol* (2019) 202(4):1229–38. doi: 10.4049/jimmunol.1801227

43. Guo Q, Subramanian H, Gupta K, Ali H. Regulation of C3a receptor signaling in human mast cells by G protein coupled receptor kinases. *PloS One* (2011) 6(7):e22559. doi: 10.1371/journal.pone.0022559

44. Gupta K, Subramanian H, Klos A, Ali H. Phosphorylation of C3a receptor at multiple sites mediates desensitization, beta-arrestin-2 recruitment and inhibition of NF-kappaB activity in mast cells. *PloS One* (2012) 7(10):e46369. doi: 10.1371/journal.pone.0046369

45. Ebo DG, Heremans K, Beyens M, van der Poorten M-LM, Van Gasse AL, Mertens C, et al. Flow-based allergen testing: Can mast cells beat basophils? *Clin Chim Acta* (2022) 532:64–71. doi: 10.1016/j.cca.2022.05.014

46. Yang F, Guo L, Li Y, Wang G, Wang J, Zhang C, et al. Structure, function and pharmacology of human itch receptor complexes. *Nature* (2021) 600 (7887):164–9. doi: 10.1038/s41586-021-04077-y

47. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. *J Allergy Clin Immunol* (1991) 88(3 Pt 1):328–38. doi: 10.1016/0091-6749(91)90094-5

48. Ebo DG, Elst J, Moorhen N, van der Poorten MM, Van Gasse AL, Garvey LH, et al. Flow-based allergen testing: A new reagent in the investigation of the chlorhexidine cross-sensitization profile. *Clin Exp Allergy* (2022). doi: 10.1111/cea.14129

49. Navines-Ferrer A, Serrano-Candelas E, Lafaire A, Munoz-Cano R, Martin M, Gastaminza G. MRGPRX2-mediated mast cell response to drugs used in peroperative procedures and anaesthesia. *Sci Rep* (2018) 8(1):11628. doi: 10.1038/s41598-018-29965-8

50. Elst J, Maurer M, Sabato V, Faber MA, Biritsh CH, Mertens C, et al. Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones. *Front Immunol* (2021) 12:668962. doi: 10.3389/fimmu.2021.668962

51. Fernandopulle NA, Zhang SS, Soeding PF, Mackay GA. MRGPRX2 activation in mast cells by neuromuscular blocking agents and other agonists: Modulation by sugammadex. *Clin Exp Allergy* (2020) 51 (7):976–7. doi: 10.1111/cea.13801

52. Garvey LH, Dewachter P, Hepner DL, Mertes PM, Voltolini S, Clarke R, et al. Management of suspected immediate peroperative allergic reactions: an international overview and consensus recommendations. *Br J Anaesth* (2019) 123(1):e50–64. doi: 10.1016/j.bja.2019.04.044

53. Leysen J, Biritsh CH, De Clerck LS, Ebo DG. Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an *in vitro* experiment. *Anaesthesia* (2011) 66(6):526–7. doi: 10.1111/j.1365-2044.2011.07298.x

54. Meixiong J, Anderson M, Limjuniawong N, Sabbagh MF, Hu E, Mack MR, et al. Activation of mast-cell-Expressed mas-related G-Protein-Coupled receptors drives non-histaminergic itch. *Immunity* (2019) 50(5):1163–71.e5. doi: 10.1016/j.immuni.2019.03.013

55. Manorek W, Idahosa C, Gupta K, Roy S, Panettieri R Jr., Ali H. Uregulation of mas-related G protein coupled receptor X2 in asthmatic lung mast cells and its activation by the novel neuropeptide hemokinin-1. *Respir Res* (2018) 19(1):1. doi: 10.1186/s12931-017-0698-3

56. Gupta K, Idahosa C, Roy S, Lee D, Subramanian H, Dhingra A, et al. Differential regulation of mas-related G protein-coupled receptor X2-mediated mast cell degranulation by antimicrobial host defense peptides and porphyromonas gingivalis lipopolysaccharide. * Infect Immun* (2017) 85(10):e00246-17. doi: 10.1128/IAI.00246-17